Menu
In the first PrevMetSyn trial 532 overweight or obese subjects (BMI 27–35 kg/m2) were recruited. Onnikka usage improved weight loss significantly independent of the type of face-to-face group councelling. The weight loss was sustained for a second year, i.e. one year after cessation of Onnikka usage. The best results (5 to 6% weight loss) were achieved when Onnikka was used on top of intensive face-to-face group counselling. However, Onnikka usage reduced body weight by about 2% even as a stand-alone application.
Metabolic syndrome is a well-known risk factor of cardiovascular diseases. A significant reduction of the prevalence of metabolic syndrome by 71% was observed among the active users of the Onnikka application by 2 years. The corresponding decrease was 55% among people who used Onnikka at average frequency. This result may be important for the prevention of public health diseases.
Half of the people received access to Onnikka immediately while the other half was randomized to a waiting list for 6 months. Only preliminary results are available so far. A significant weight reduction was observed among Onnikka users whereas those in the waiting list had a slight gain in body weight.
A new trial is also underway in general practice offices near Oulu (Muhos, Kempele, Liminka and Ii). The Onnikka application is available for patients with at least two cardiovascular risk factors in addition to obesity. This trial is also a long-term study and results will be ready after two years.